Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 10/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | MIF | P14174 | 1/20 | 0.59 |
| ▸ | IDO1 | P14902 | 4/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | MYC | P01106 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAX | P61244 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18085190 | 0.87 | GSTM2 (0.58) | GSTM2MEN1KMT2AUSP2HTT | |
| Bromide SCHEMBL30275948 | 0.86 | GSTM2 (0.66) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL28069116 | 0.85 | GSTM2 (0.68) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL17781757 | 0.85 | MEN1 (0.67) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL19222011 | 0.84 | GSTM2 (0.67) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL12818156 | 0.83 | GSTM2 (0.70) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL13252252 | 0.83 | GSTM2 (0.73) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL28945751 | 0.83 | GSTM2 (0.59) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL19387685 | 0.82 | GSTM2 (0.68) | GSTM2MEN1KMT2AUSP2HTT | |
| SCHEMBL8427071 | 0.82 | GSTM2 (0.68) | GSTM2MEN1KMT2AUSP2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101943-A1 | ANTI-HUMAN CLAUDIN-18.2 ANTIBODIES FOR IN VITRO DIAGNOSTICS | AGILENT TECHNOLOGIES, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4594350-A1 | ANTI-HUMAN HOMEOBOX PROTEIN NKX-2.1 ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND FOR DIAGNOSING CANCER | Agilent Technologies, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| CN-119998315-A | Use of anti-human homeobox protein NKX-2.1 antibodies for Immunohistochemical (IHC) protocols and for diagnosis of cancer | 安捷伦科技有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119855833-A | Anti-human ICOS antibodies for use in Immunohistochemical (IHC) protocols and for diagnosis of cancer | 安捷伦科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| WO-2025064990-A1 | ANTI-HUMAN ADAM9 ANTIBODIES FOR IN VITRO DIAGNOSTICS | AGILENT TECHNOLOGIES, INC. (US) | 2025-03-27 | — | — | WO | claimed |
| US-20250084452-A1 | BIOLOGICAL INDICATOR FOR DETERMINING THE EFFICACY OF A STERILIZATION PROCESS AND METHODS OF USE | TERRAGENE LLC | 2025-03-13 | — | — | US | claimed |
| WO-2024072902-A1 | ANTI-HUMAN HOMEOBOX PROTEIN NKX-2.1 ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS AND FOR DIAGNOSING CANCER | AGILENT TECHNOLOGIES, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| EP-4255932-A1 | ANTI-HUMAN CD10 ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER | Agilent Technologies, Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-4244258-A1 | CHIMERIC ANTI-HUMAN BRAF V600E ANTIBODIES AND METHODS FOR MAKING AND USING THEM | Agilent Technologies, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| WO-2023167903-A2 | ANTI-HUMAN B CELL MATURATION ANTIGEN (BCMA) ANTIBODIES AND THEIR USE IN IMMUNOHISTOCHEMISTRY (IHC) | AGILENT TECHNOLOGIES, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| CN-116635718-A | Anti-human CD10 antibodies for use in Immunohistochemical (IHC) protocols to diagnose cancer | 安捷伦科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-116615660-A | Chimeric anti-human BRAF V600E antibodies and methods of making and using the same | 安捷伦科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| EP-4204451-A1 | ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER | Agilent Technologies, Inc. (US) | 2023-07-05 | — | — | EP | claimed |
| CN-116234823-A | Antibodies for diagnosing cancer in an Immunohistochemical (IHC) protocol | 安捷伦科技有限公司 | 2023-06-06 | — | — | CN | claimed |
| CN-115667304-A | Anti-human LAG-3 antibodies and their use in Immunohistochemistry (IHC) | 安捷伦科技有限公司 | 2023-01-31 | — | — | CN | claimed |
| WO-2022119932-A1 | ANTI-HUMAN CD10 ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER | AGILENT TECHNOLOGIES, INC. (US) | 2022-06-09 | — | — | WO | claimed |
| WO-2022104200-A1 | CHIMERIC ANTI-HUMAN BRAF V600E ANTIBODIES AND METHODS FOR MAKING AND USING THEM | AGILENT TECHNOLOGIES, INC. (US) | 2022-05-19 | — | — | WO | claimed |
| WO-2022046885-A1 | ANTIBODIES FOR USE IN IMMUNOHISTOCHEMISTRY (IHC) PROTOCOLS TO DIAGNOSE CANCER | AGILENT TECHNOLOGIES, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2026101943-A1 | ANTI-HUMAN CLAUDIN-18.2 ANTIBODIES FOR IN VITRO DIAGNOSTICS | AGILENT TECHNOLOGIES, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20090306125-A1 | Mitochondria-Targeted Antioxidant Prodrugs and Methods of Use | UNIVERSITY OF ROCHESTER | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306125-A1 | Mitochondria-Targeted Antioxidant Prodrugs and Methods of Use | TXNRD2, HADHA, PRDX5 | GSTM2 231/4885MEN1 4481/4885KMT2A 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.